Mara Aspinall, Founder, DxInsights
Listen (2:43) DxInsights and EPEMED
Listen (3:53) Diagnostics 5.0
Listen (2:43) International School of Biomedical Diagnostics
Listen (3:43) FDA Guidance on LDTs: the right time? the right move?
Listen (3:53) Angelina Jolie: a teaching moment
Listen (4:17) What translational gap?
Listen (1:56) Educating payers
You could call her Ms. Dx Education. Mara Aspinall has served as CEO of diagnostics companies big and small, but she’s also spent a great deal of time building a diagnostics community. Some of the early meetings of the Personalized Medicine Coalition took place in her home.
Recently Mara has stepped up her efforts in diagnostics education: that of the industry players, of physicians, and also of the next generation. She’s a co-founder of DxInsights, a new non-profit focused on better education that has already put on their first conference. DxInsights recently announced a partnership with EPEMED, or the European version of the Personalized Medicine Coalition, to create a new Knowledge Center. She is perhaps most proud of helping to create a new International School of Biomedical Diagnostics which has enrolled their first graduate students this year. This school is a first of its kind, pulling faculty expertise from various organizations in Southern Arizona as well as Dublin City University.
“We have medical school students requesting that sequencing--and what I call “Diagnostics 5.0”-- be a part of their curriculum, and it has not been,” she says in today’s interview.
Mara is a supporter of the FDA’s recent move on LDTs, saying that the current system for diagnostics has not been working. She thinks new regulation that levels the playing field among the various players will help to spur business and innovation because it offers a more predictable path to market.
We end with her thoughts on physician and payer education.
Podcast brought to you by: Slone Partners - Premier talent. Delivered.